Endeavour Medtech reports 5.7% stake in Rapid Micro

Rhea-AI Filing Summary

Rapid Micro Biosystems, Inc. (RPID) received an updated ownership disclosure showing that investment entities affiliated with Endeavour Medtech collectively report beneficial ownership of 2,257,099 shares of Class A common stock, representing 5.7% of the class, based on 39,823,026 shares outstanding as of October 31, 2025.

The shares are held of record by Endeavour Medtech Growth II LP (2,217,190 shares) and Endeavour Medtech Growth II Parallel LP (39,909 shares), with Endeavour Medtech II GP Limited as general partner. The reporting group certifies the holdings are not for the purpose of changing or influencing control of the company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Rapid Micro Biosystems (RPID) does Endeavour Medtech report owning?

Endeavour Medtech–affiliated entities report beneficial ownership of 5.7% of Rapid Micro Biosystems’ Class A common stock. This percentage is calculated using 39,823,026 shares outstanding as of October 31, 2025, as disclosed in the company’s Form 10-Q.

How many Rapid Micro Biosystems (RPID) shares does Endeavour Medtech beneficially own?

Endeavour Medtech–related entities report beneficial ownership of 2,257,099 shares of Rapid Micro Biosystems’ Class A common stock. This total combines 2,217,190 shares held by Endeavour Medtech Growth II LP and 39,909 shares held by Endeavour Medtech Growth II Parallel LP.

Which entities are the reporting persons in the Rapid Micro Biosystems (RPID) Schedule 13G/A?

The Schedule 13G/A is filed on behalf of Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited. Each is organized in Guernsey and together they report shared voting and dispositive power over the disclosed shares.

Does Endeavour Medtech seek to influence control of Rapid Micro Biosystems (RPID)?

The reporting group certifies the securities were not acquired and are not held to change or influence control of Rapid Micro Biosystems. They also state the holdings are not in connection with any transaction having that purpose, other than specified nomination-related activities.

How are voting and dispositive powers over Rapid Micro Biosystems (RPID) shares allocated?

The reporting persons indicate 0 shares with sole voting or dispositive power and 2,257,099 shares with shared voting and shared dispositive power. This means decisions about voting and selling these shares are made jointly among the reporting entities, rather than by any one alone.

What reference date and outstanding share count were used in this Rapid Micro Biosystems (RPID) 13G/A?

The ownership percentage is based on 39,823,026 Class A shares outstanding as of October 31, 2025, as reported in Rapid Micro Biosystems’ Form 10-Q filed on November 7, 2025. The 13G/A event date is listed as December 31, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:50 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Rapid Micro Biosystems, Inc.

(Name of Issuer)

Common Stock, par value $0.01

(Title of Class of Securities)

75340L104

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 75340L104

1

Names of Reporting Persons

Endeavour Medtech Growth II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GUERNSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,257,099.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,257,099.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,257,099.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP. (2) Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025 (the "Form 10-Q").

SCHEDULE 13G

CUSIP No. 75340L104

1

Names of Reporting Persons

Endeavour Medtech Growth II Parallel LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GUERNSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,257,099.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,257,099.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,257,099.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP. (2) Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025.

SCHEDULE 13G

CUSIP No. 75340L104

1

Names of Reporting Persons

Endeavour Medtech II GP Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GUERNSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,257,099.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,257,099.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,257,099.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (3) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP. (4) Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Rapid Micro Biosystems, Inc.
(b)	Address of issuer's principal executive offices: 25 Hartwell Avenue, Lexington, MA 02421
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i) Endeavour Medtech Growth II LP (ii) Endeavour Medtech Growth II Parallel LP (iii) Endeavour Medtech II GP Limited
(b)	Address or principal business office or, if none, residence: The address of the principal business and principal office of each of the Reporting Persons is P.O. Box 656, East Wing Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3PP
(c)	Citizenship: Each of (1) Endeavour Medtech Growth II LP, (2) Endeavour Medtech Growth II Parallel LP and (3) Endeavour Medtech II GP Limited is a Guernsey limited partnership.
(d)	Title of class of securities: Common Stock, par value $0.01
(e)	CUSIP No.: 75340L104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Endeavour Medtech Growth II LP 2,217,190 shares of Class A common stock are held of record by Endeavour Medtech Growth II LP ("EMG II"). Endeavour Medtech II GP Limited ("Endeavour GP") is the general partner of EMG II. Endeavour Medtech Growth II Parallel LP 39,909 shares of Class A common stock are held of record by Endeavour Medtech Growth II Parallel LP ("EMG II AFF"). Endeavour GP is the general partner of EMG II AFF. As a result of foregoing, and the relationships described in Item 2(a) of this Schedule 13G, the Reporting Persons may be deemed to share ownership over the reported 2,257,099 shares of Class A common stock, but the filing of this Statement shall not be deemed an admission of such beneficial ownership by any of the Reporting Persons for purposes of Section 13(d) or Section 13(g) or for any other purpose.
(b)	Percent of class: 5.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,257,099
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 2,257,099
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Endeavour Medtech Growth II LP

Signature:	/s/ Nick Barton
Name/Title:	Nick Barton, Director
Date:	02/13/2026

Endeavour Medtech Growth II Parallel LP

Signature:	/s/ Nick Barton
Name/Title:	Nick Barton, Director
Date:	02/13/2026

Endeavour Medtech II GP Limited

Signature:	/s/ Nick Barton
Name/Title:	Nick Barton, Director
Date:	02/13/2026

Comments accompanying signature: Endeavour Medtech Growth II LP is signed for by Endeavour Medtech II GP Limited, its General Partner. Endeavour Medtech Growth II Parallel LP is signed for by Endeavour Medtech II GP Limited, its General Partner..